POLARIS

• Results of a cost-effectiveness analysis in the United States demonstrated a reduction in MI, revascularization, and cardiac death among general CAD population treated with IVUS as compared to angiography alone.¹
  
• IVUS was particularly effective in high risk subgroups, specifically in patients with diabetes, ACS, and Impaired Renal Function.²
  
• Evidence suggests that IVUS reduces the rate of severe cardiac events at 30 days, which may result in fewer MI related readmissions. Thirty-day readmissions are measured under the US CMS readmissions reduction program.³
• Over the lifetime of a CAD patient, IVUS could potentially save a total of $2,142 as compared to angiography alone.¹
• The potential savings are even higher ($2,997, $2,879, and $3,257) when modeling patients with diabetes, ACS, and impaired renal function.¹

Adverse cardiac events are a substantial burden to the health system:

• Cost per MI: $8,039^*
• Cost per revascularization: $12,948^†